Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: JACC Heart Fail. 2019 Apr 29;7(7):586–598. doi: 10.1016/j.jchf.2019.04.004

TABLE 3.

Treatment Emergent Adverse Events

Endpoint Bucindolol
(N=134)		 Metoprolol
(N=133)
Any adverse event (AE) 100 (74.6%) 95 (71.4%)
AE possible/probably related to study drug 32 (23.9%) 40 (30.1%)
AE leading to permanent study drug discontinuation 11 (8.2%) 11 (8.3%)
AE leading to study withdrawal (excluding death) 2 (1.5%) 2 (1.5%)
AE of symptomatic bradycardia or bradycardia leading to dose reduction or discontinuation of study drug 4 (3.0%) 12 (9.0%)
Any serious adverse event 34 (25.4%) 27 (20.3%)
AE leading to death 3 (2.3%) 3 (2.3%)

Data presented from randomization through 30 days after last dose of study drug.